Tinengotinib
Small molecule
Also known as TT-00420
Evidence outlook · registrational
Cholangiocarcinoma: registrational readout pending
Entered Phase 3 on weak signal mid-stage evidence. Registrational readout expected around 2026-12.
NCT05253053: This was a nonrandomized, open-label study with three treatment arms and no placebo or active comparator; 84 participants were enrolled. Its primary outcomes concerned treatment-related adverse events, laboratory abnormalities, and dose-limiting toxicity, and no primary endpoint results have been posted.
Also in development:HR+/HER2- Metastatic Breast Cancer · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT04742959 NCT04742959 · Advanced Solid Tumor, Cholangiocarcinoma, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Bladder Cancer, Small-cell Lung Cancer, Prostate Cancer, Thyroid Cancer, Sarcoma, Gastric Cancer, Gallbladder Cancer The study was non-randomized and open-label, with three experimental cohorts and no placebo or active comparator, despite enrolling 203 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence. Registry: NCT04742959 | 1/2 | Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment (Up to 30 days from study discontinuation); Dose limiting toxicity (DLT) (Up to 28 days from the first dose) 2024-02-20 | TRAEs in the monotherapy safety population (NCT04742959): 74% any-grade, 36% grade 3, 1.2% grade 4, no treatment-related deaths; most common TRAEs hypertension 32%, stomatitis 22.1%, diarrhea 16.3%, palmar-plantar erythrodysesthesia syndrome 14%, nausea 12.8%, fatigue 10.5%. | Weak signal | link ↗ |
View 3 more trials
FIRST-308 NCT05948475 · Cholangiocarcinoma Registry: NCT05948475 | 3 | Part A: Incidence, duration, and severity of adverse events (AEs) (Up to 30 days from study discontinuation); Part B: PFS by BICR (From first study drug administration until the date of first documented progression assessed by BICR or date of death from any cause, whichever came first, assessed up to 24 months) 2026-12 | In progress: results expected 1 Dec 2026 | not yet graded | link ↗ |
NCT07328919 NCT07328919 · Intrahepatic Cholangiocarcinoma (Icc) Registry: NCT07328919 | 3 | PFS by BICR (From first study drug administration until the date of first documented progression assessed by BICR or date of death from any cause, whichever came first, assessed up to 24 months.) 2029-12-31 | In progress: results expected 31 Dec 2029 | not yet graded | link ↗ |
NCT05253053 NCT05253053 · Advanced Solid Tumor, Cholangiocarcinoma, Biliary Tract Cancer, HER2-negative Breast Cancer, Triple Negative Breast Cancer, Small-cell Lung Cancer, Bladder Cancer, Prostate Cancer, Thyroid Cancer, Gastric Cancer, Gallbladder Cancer This was a nonrandomized, open-label study with three treatment arms and no placebo or active comparator; 84 participants were enrolled. Its primary outcomes concerned treatment-related adverse events, laboratory abnormalities, and dose-limiting toxicity, and no primary endpoint results have been posted. Registry: NCT05253053 | 1/2 | Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment (Up to 30 days from the last dose); Dose limiting toxicity (DLT) (Up to 21 days from the first dose) 2024-08-31 | Results not posted; external-source review pending | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (4)
What this study did
What this study did
What this study did
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Cholangiocarcinoma: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Tinengotinib: this drug | Phase 3 | Small molecule | Aurora A/B kinase (with secondary FGFR1/2/3, VEGFR1, JAK1/2, CSF1R inhibition) | Weak signal | Featured results are safety only in this race | |
| Futibatinib (Lytgobi) | Approved | Small molecule | FGFR (FGFR1/2/3/4) | Weak signal | No reviewed efficacy summary in this indication | |
| Lirafugratinib (Lyrfigtu) | Approved | Small molecule | FGFR2 | not yet graded | No reviewed efficacy summary in this indication | |
| Pemigatinib (Pemazyre) | Approved | Small molecule | FGFR1/2/3 | Weak signal | No reviewed efficacy summary in this indication | |
| Zenocutuzumab (Bizengri) | Approved | Multispecific antibody | HER2; HER3 (blocks NRG1 binding to HER3) | not yet graded | No reviewed efficacy summary in this indication | |
| Toripalimab | Phase 3 | Monoclonal antibody | PD-1 | not yet graded | No reviewed efficacy summary in this indication | |
| Crelosidenib | Phase 1 | Small molecule | Mutant IDH1 and IDH2 | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(6 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Tinengotinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.